CoChat

Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes

Birzniece, Vita, Ho, Ken K Y · 2015 · European Journal of Endocrinology

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Context: Tamoxifen, a selective estrogen receptor modulator, suppresses GH secretion in women but not in men. It increases testosterone levels in men. As GH and testosterone stimulate fat metabolism, the metabolic consequences of tamoxifen may be greater in women than in men. Objective: To determine whether tamoxifen suppresses fat oxidation (Fox) to a greater degree in women than in men. Design: An open-label study of ten healthy postmenopausal women and ten healthy men receiving 2-week treatment with tamoxifen (20 mg/day). Endpoint measures: GH response to arginine stimulation, serum levels of IGF1, testosterone and LH (men only), sex hormone binding globulin (SHBG) and whole body basal and postprandial Fox. Results: In women, tamoxifen significantly reduced the mean GH response to arginine stimulation (Δ −87%,P<0.05) and circulating IGF1 levels (Δ −23.5±5.4%,P<0.01). Tamoxifen reduced postprandial Fox in women (Δ −34.6±10.3%;P<0.05). In men, tamoxifen did not affect the GH response to arginine stimulation but significantly reduced mean IGF1 levels (Δ −24.8±6.1%,P<0.01). Tamoxifen increased mean testosterone levels (Δ 52±14.2%;P<0.01). Fox was not significantly affected by tamoxifen in men. Conclusion: Tamoxifen attenuated the GH response to stimulation and reduced postprandial Fox in women but not in men. We conclude that at a therapeutic dose, the suppressive effect of tamoxifen on fat metabolism is gender-dependent. Higher testosterone levels may mitigate the suppression of GH secretion and Fox during tamoxifen treatment in men.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-15-0426

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. 10.1210/jc.76.6.1407 · doi:10.1210/jc.76.6.1407 · Paper page

Cited by

See all 8

Metadata

Authors
Birzniece, V., & Ho, K. K. Y.
Affiliations
Garvan Institute of Medical Research (AU)
Corresponding author
Ho, Ken K Y
Venue
European Journal of Endocrinology
Published
2015-10
Volume
173
Issue
4
Pages
479-487
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W1929970298
Cited by
8
References
39
Citations by year
2025: 1 · 2019: 2 · 2017: 4 · 2016: 1
FWCI
1.45
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
tamoxifen, estrogen receptor antagonism, selective estrogen receptor modulators, fat oxidation, growth hormone secretion, insulin-like growth factor I, testosterone, sex differences, postmenopausal women, arginine stimulation, sex hormone-binding globulin, gonadal axis
MeSH terms
Adipose Tissue, Aged, Estrogen Antagonists, Female, Humans, Insulin-Like Growth Factor I, Luteinizing Hormone, Male, Middle Aged, Oxidation-Reduction, Sex Characteristics, Sex Hormone-Binding Globulin, Tamoxifen, Testosterone, Postmenopause, Human Growth Hormone, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. https://app.cochat.ai/papers/10.1530/eje-15-0426
The paper
Birzniece, V., & Ho, K. K. Y. (2015). Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. European Journal of Endocrinology. https://doi.org/10.1530/eje-15-0426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.